VisceraLink Selective Sensory Vagal Interface: a bionic platform for internal organ modulation
- Coordinator
- Medizinische Universitaet Wien, Austria
- Runs
- 1 January 2027 to 31 December 2031
- Status
- Running
- EU funding
- €2.2m
- Total cost
- €2.2m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101301600
What the project is doing
In the project's own words, from its summary on CORDIS.
Most organ functions unfold beneath our awareness. We sense the heart, gut, and vessels through interoception, yet this sensing rarely reaches perception; instead, afferent messages tune reflexes that set heart rate, blood pressure, and metabolic tone. In disease and chronic dysregulation, these pathways are corrupted. If we can encode the right sensory messages, we can steer those reflexes – and organ function. Two prominent dysregulations are hypertension and obesity – each affects >1 billion people, drives premature mortality, and often resists durable control despite lifestyle change and multi-drug therapy.
To address this need, I will develop VisceraLink: a sensory-first interface on organ-specific vagal branches, paired with an actuator that reproduces natural mechanical signals the brain already understands – enabling organ-specific, feedback-guided autonomic control. Two tracks structure the work. Cardiovascular: engage the baroreflex via the aortic depressor pathway to reduce arterial pressure. Metabolic: engage vagovagal reflexes via gastric branches to adjust motility, satiety, and metabolic tone.
I will map and select branch targets, redirect them into living biologic grafts that reinnervate to form a sensory hub, and integrate a programmable actuator to deliver tonic and pulsatile distension that drives the intended reflexes. The program targets translation-critical steps: branch selection, construction of the biohybrid sensory interface, integration of an implant-ready biomimetic actuator, and a clear input-to-effect map for closed-loop use.
Out-of-surgery preclinical testing will confirm durability, usability, and safety, positioning VisceraLink for early human evaluation. If successful, VisceraLink establishes a first-in-kind platform for selective, intuitive, and repeatable autonomic modulation, a practical way to write the body’s visceral code, delivering organ-specific therapies for resistant hypertension and obesity, scalable to other conditions.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Medizinische Universitaet Wien | Wien | Austria | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS